A Consortium for Cancer | GenomeWeb

A Consortium for Cancer


Despite advances in cancer therapeutics, tumor heterogeneity remains a major challenge when developing techniques for personalized diagnosis and prediction of response to treatment. While cancer research is increasingly moving toward turning tumor-specific biomarkers into diagnostic tools, there is still a need for an improved systematic approach to biomarker discovery and quantification before cutting-edge, targeted therapies can be broadly implemented.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.